Skip to main content
. 2008 Oct 22;116(2):371–378. doi: 10.1007/s10549-008-0161-8

Table 2.

Analysis of clinical, mammogram and ultrasound response data according to aromatase protein expression status in tamoxifen or letrozole treated patients

Responses Aromatase protein expression [n (%)]
Tumor epithelial aromatase Stromal aromatase
Negative Positive Negative Positive
Clinical responsea
Letrozole only
    No 6 (29%) 24 (32%) 11 (44%) 18(26)
    Yes 15 (71%) 51 (68%) 14 (56%) 51(74)
    P-value 0.7657 0.0984
Tamoxifen only
    No 12 (50%) 37 (51%) 13 (45%) 34 (54%)
    Yes 12 (50%) 35 (49%) 16 (55%) 29 (46%)
    P-value 0.9067 0.4177
Fused
    No 18 (40%) 61 (41%) 24 (44%) 52 (39%)
    Yes 27 (60%) 86 (59%) 30 (56%) 80 (61%)
    P-value 0.8587 0.5259
Mammo responsea
Letrozole only
    No 13 (62%) 47 (63%) 17 (68%) 42 (61%)
    Yes 8 (38%) 28 (37%) 8 (32%) 27 (39%)
    P-value 0.9494 0.5297
Tamoxifen only
    No 19 (79%) 54 (75%) 23 (79%) 48 (76%)
    Yes 5 (21%) 18 (25%) 6 (21%) 15 (24%)
    P-value 0.6803 0.7418
Fused
    No 32 (71%) 101 (69%) 40 (74%) 90 (68%)
    Yes 13 (29%) 46 (31%) 14 (26%) 42 (32%)
    P-value 0.7604 0.4278
Ultrasound responsea
Letrozole only
    No 12 (67%) 39 (56%) 16 (73%) 34 (52%)
    Yes 6 (33%) 31 (44%) 6 (27%) 31 (48%)
    P-value 0.4038 0.0959
Tamoxifen only
    No 13 (68%) 44 (64%) 15 (60%) 41 (69%)
    Yes 6 (32%) 25 (36%) 10 (60%) 18 (31%)
    P-value 0.7085 0.4016
Fused
    No 25 (68%) 83 (60%) 31 (66%) 75 (60%)
    Yes 12 (32%) 56 (40%) 16 (34%) 49 (40%)
    P-value 0.3845 0.5116

Response rate refers to the percentage of patients with a complete or partial response

aResponse definitions by WHO criteria have been previously reported [11]. The X2 test was applied with Fisher’s exact test if a count in any cell was less than 5